{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bronchiectasis/management/suspected-bronchiectasis/","result":{"pageContext":{"chapter":{"id":"0180d43c-dd8d-5a87-915c-629542f782fe","slug":"suspected-bronchiectasis","fullItemName":"Scenario: Suspected bronchiectasis","depth":2,"htmlHeader":"<!-- begin field 09e2984f-3d86-4560-a2b1-b683b19ac4ee --><h2>Scenario: Suspected bronchiectasis</h2><!-- end field 09e2984f-3d86-4560-a2b1-b683b19ac4ee -->","summary":"Covers the management of suspected bronchiectasis.","htmlStringContent":"<!-- begin item a6780e41-83a6-40c2-8c96-2642dc2b0c68 --><!-- begin field 9264a389-35dc-4355-8ebc-acd900acb7d5 --><p>From age 12 months onwards.</p><!-- end field 9264a389-35dc-4355-8ebc-acd900acb7d5 --><!-- end item a6780e41-83a6-40c2-8c96-2642dc2b0c68 -->","topic":{"id":"96a8622b-46f5-55fa-b729-6748e3d98c98","topicId":"26fab339-e333-44ec-a481-de87a29052f3","topicName":"Bronchiectasis","slug":"bronchiectasis","lastRevised":"Last revised in January 2021","chapters":[{"id":"43d88c30-f768-5e1c-a6ea-5596c5577fb5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac4fde9a-5fd3-5ed9-9201-f714bda470bb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0b34af83-d49a-5145-8589-e8748b8646c0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04eeb1ae-4fc3-5418-83a2-b62587d8bdda","slug":"changes","fullItemName":"Changes"},{"id":"dbd8ad5a-871c-59b8-9729-444e11ac9df1","slug":"update","fullItemName":"Update"}]},{"id":"b89644c6-805f-50b4-991d-36bb2b0fbf67","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d38de329-73b8-5fed-83ef-f836b765cd3f","slug":"goals","fullItemName":"Goals"},{"id":"3c116665-5586-5551-909c-0efc1ef0be62","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"60e13bc0-e351-5c39-b8ff-9a8d4514bf16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ee37cc0-9ff4-5bbd-ab3f-0a30cb904bb5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d155aa4f-7dfe-575d-a7dd-a87774f4cbad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"07c3e24b-c950-516e-9070-5441a07b3791","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5146c866-f0a7-54a6-a5ac-8aff4b385cc6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e2107a7e-b7c3-5ba9-94e4-6217ea79a3f2","slug":"definition","fullItemName":"Definition"},{"id":"39df7c47-de08-57ae-aa40-89a7d4d7b031","slug":"causes","fullItemName":"Causes"},{"id":"ac4d346e-97d4-5d84-a704-fbdcf56be7f4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e07a8b0b-866c-5789-85ef-020a5b19b620","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"ef5c5e7b-3cf4-5939-85e0-b61cae41f945","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ce267b5b-70dd-52bd-ad83-6123bd42fa0d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c605c0b9-0519-50e1-abd8-2dc47de7278a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"23a1627d-30f7-5ba4-95f8-060faf797f51","slug":"suspected-infective-exacerbation-diagnosis","fullItemName":"Suspected infective exacerbation diagnosis"}]},{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","fullItemName":"Management","slug":"management","subChapters":[{"id":"0180d43c-dd8d-5a87-915c-629542f782fe","slug":"suspected-bronchiectasis","fullItemName":"Scenario: Suspected bronchiectasis"},{"id":"290c51ae-6521-5c03-b12e-117e40c88883","slug":"infective-exacerbation","fullItemName":"Scenario: Infective exacerbation"},{"id":"1e90ec28-8eea-5ab7-ac76-2df1ace279de","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6db0266e-4d15-5eec-b2c0-ed20f472eeb5","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"a98b5813-5589-5247-9c65-e9ae534d88c2","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"04c99c8f-7a1d-55f0-85a2-6d0e1bc3e4e3","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"26b521e3-9c5e-5a7c-956b-7f3f39f2e58c","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"6cd6079a-be84-5279-9d10-e3bf4653c049","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"8ed4a900-3e69-51c0-8cd5-c2b0bee9bfe2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"5217d027-064d-5543-93b0-7e8bb1a1c0fc","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cf1fbf18-e60a-54f7-bbc4-2a30ab37f565","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8e888abe-cb05-5343-b6e3-547dea7312cc","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"}]},{"id":"118b4e08-e6ae-510a-b2f5-51b109ef3395","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecf8de37-d8f0-5ced-af38-9be20fa73de9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1c227675-02ea-5c9e-a927-e385987adf53","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f74bbe64-1998-528f-b811-df2a14219de7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a925d45-6865-5cd5-9624-23da53ee221a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a6ff3076-9be6-55b4-b373-f40cb3045f2c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67608f46-5eba-58f9-86e3-0e0e3f57d921","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3fae7f8d-20fb-5fe6-af57-64882afceb3a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d11fd90b-f640-51c3-8486-f7d2df730468","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 2f84168e-1216-4237-9753-511ac72823ef --><h3>How should I manage a person with suspected bronchiectasis?</h3><!-- end field 2f84168e-1216-4237-9753-511ac72823ef -->","summary":null,"htmlStringContent":"<!-- begin item 5c723ecf-4219-44bb-a43c-0a59ea7adc75 --><!-- begin field 65f187ed-ebe7-43a5-bd26-e142443c2542 --><ul><li><strong>If bronchiectasis is <a class=\"topic-reference internal-reference\" href=\"/topics/bronchiectasis/diagnosis/diagnosis/\">suspected</a>: </strong><ul><li><strong>Take a thorough history. </strong></li><li><strong>Arrange the following investigations:</strong><ul><li>Sputum culture — to identify colonizing pathogens. Public Health England gives detailed <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/483833/B_57i3.1.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"65d78256-df05-4804-8cf5-a993005b35c3\">guidance</a> on the collection and transport of respiratory tract specimens.</li><li>Chest X-ray — to exclude other pathology and to help confirm the diagnosis where disease is severe.</li><li>Spirometry — to assess the severity of airflow obstruction and identify any co-existent diagnoses (such as chronic obstructive pulmonary disease [COPD]).</li><li>Oxygen saturation levels.</li><li>Full blood count including differential white cell count. </li><li>Other investigations — guided by clinical findings to confirm or rule out underlying causes for bronchiectasis.</li></ul></li><li><strong>Assess for the presence of anxiety or depression,</strong> particularly in people who have severe breathlessness. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>. </li><li><strong>Document the person's smoking history </strong>— if they currently smoke, offer support to stop. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li><li><strong>Measure the person's weight and calculate and document the person's body mass index</strong> (weight in kg/height in m<sup>2</sup>).</li></ul></li><li><strong>Refer all people with suspected bronchiectasis to a respiratory consultant </strong>for <a class=\"topic-reference internal-reference\" href=\"/topics/bronchiectasis/diagnosis/diagnosis/\">investigations</a> to confirm the diagnosis and determine the underlying cause, and for appropriate treatment.</li></ul><!-- end field 65f187ed-ebe7-43a5-bd26-e142443c2542 --><!-- end item 5c723ecf-4219-44bb-a43c-0a59ea7adc75 -->","subChapters":[{"id":"9e7dac83-ed39-51fd-8cc6-7b87287fc56b","slug":"investigations-in-secondary-care","fullItemName":"Investigations in secondary care","depth":4,"htmlHeader":"<!-- begin field 9fa989c9-9e5d-41b8-b6bb-90153c0f9f7f --><h4>Investigations in secondary care</h4><!-- end field 9fa989c9-9e5d-41b8-b6bb-90153c0f9f7f -->","summary":null,"htmlStringContent":"<!-- begin item 86831117-ab5c-486f-bf17-2b362556d345 --><!-- begin field a02fc76b-66c1-4191-92f4-2ea17c015188 --><ul><li><strong>High-resolution computed tomography (HRCT) </strong>(thin section scanning) is the most frequently used imaging test to establish the diagnosis of bronchiectasis. </li><li>Investigations to determine the underlying cause of bronchiectasis include:<ul><li><strong>Testing for cystic fibrosis </strong>(such as sweat chloride or gene testing) — for all children, adults up to 40 years of age, and adults older than 40 years of age with clinical features consistent with cystic fibrosis.</li><li><strong>Screening for gross antibody deficiency</strong> (serum immunoglobulin G [IgG], IgA, IgM) — for all people with confirmed bronchiectasis. </li><li><strong>Serum total immunoglobulin </strong>IgE and specific IgE or skin prick test to Aspergillus — to exclude allergic bronchopulmonary aspergillosis. </li><li><strong>Specific antibody levels </strong>against capsular polysaccharides of <em>Streptococcus pneumonia. </em></li><li><strong>Test for primary ciliary dyskinesia </strong>— for children where no other cause for bronchiectasis is identified and if there is a history of continuous rhinitis, neonatal respiratory distress, and/or dextrocardia; and for adults if there is a history of upper respiratory tract problems or otitis media.</li></ul></li><li><strong>Other investigations that may be considered, depending on clinical features, include: </strong><ul><li>Test for rheumatoid factor, anti-cyclic citrullinated peptide (anti-CPP), antinuclear antibodies, and anti-neutrophil cytoplasmic antibodies (ANCA). </li><li>HIV-1 serology. </li><li>Test for alpha 1 antitrypsin (A1AT) deficiency.</li><li>Gastrointestinal investigations.</li><li>Serum protein electrophoresis (in people with raised immunoglobulins). </li><li>Bronchoscopy — for people with localized disease to rule out an endobronchial lesion, or foreign body aspiration.</li></ul></li></ul><!-- end field a02fc76b-66c1-4191-92f4-2ea17c015188 --><!-- end item 86831117-ab5c-486f-bf17-2b362556d345 -->","subChapters":[]},{"id":"e02bfd35-c602-53ee-9486-9eb9d73866b4","slug":"follow-up-in-secondary-care","fullItemName":"Follow up in secondary care","depth":4,"htmlHeader":"<!-- begin field b1ea3e93-e3e6-43bd-b453-a9ba00b99af8 --><h4>Who should be followed up in secondary care?</h4><!-- end field b1ea3e93-e3e6-43bd-b453-a9ba00b99af8 -->","summary":null,"htmlStringContent":"<!-- begin item e0875c5b-50fe-4d05-ae1e-a9ba00b999bf --><!-- begin field fe4db692-051d-45fa-b201-a9ba00b99af8 --><p>People at high risk of future exacerbations should be reviewed in secondary care, including those who have: </p><ul><li>Had three or more exacerbations in a year. </li><li>Chronic <em>Pseudomonas aeruginosa</em>, methicillin-resistant <em>Staphylococcus aureus</em>, or non-tuberculous mycobacteria colonization. </li><li>Deteriorating bronchiectasis with declining lung function or advanced disease. </li><li>Allergic pulmonary aspergillosis. </li><li>Long-term antibiotic therapy.</li><li>Associated rheumatoid arthritis, immune deficiency, inflammatory bowel disease, allergic bronchopulmonary aspergillosis, or primary ciliary dyskinesia. </li><li>Advanced disease and those considering lung transplantation.</li></ul><!-- end field fe4db692-051d-45fa-b201-a9ba00b99af8 --><!-- end item e0875c5b-50fe-4d05-ae1e-a9ba00b999bf -->","subChapters":[]},{"id":"2a83a022-955d-56dc-a408-14c5ba11caa1","slug":"basis-for-recommendation-1a8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fadf78af-91b3-4f3e-b4a2-3dad015cdd4a --><h4>Basis for recommendation</h4><!-- end field fadf78af-91b3-4f3e-b4a2-3dad015cdd4a -->","summary":null,"htmlStringContent":"<!-- begin item 1a8b5e3a-1459-4412-8468-7ff497b700aa --><!-- begin field 685a0df4-db13-478b-9723-6965d6624136 --><p>These recommendations are based on the British Thoracic Society (BTS) <em>Guideline for non-CF bronchiectasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2010</a>], the BTS<em> Guideline for bronchiectasis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2019</a>], the <em>European Respiratory Society guidelines for the management of adult bronchiectasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Polverino, 2017</a>], and expert opinion in a narrative review<em> Primary care implications of the British Thoracic Society Guidelines for bronchiectasis in adults 2019 </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Gruffydd-Jones, 2019</a>].</p><h5>Chest X-ray</h5><ul><li>Chest X-ray is not recommended for diagnosis as findings are non-specific in bronchiectasis and may even be normal [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BMJ, 2020</a>]. </li><li>Chest X-ray has limited sensitivity and specificity in diagnosing bronchiectasis particularly in mild disease, however, the BTS recommends that a baseline X-ray should be performed in people with suspected bronchiectasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2019</a>] (this is a grade D recommendation).<ul><li>Compared with high-resolution computed tomography (HRCT) the sensitivity of chest X-ray is 87.8% and specificity 74.4%.</li></ul></li></ul><h5>Spirometry</h5><ul><li>In adults with bronchiectasis, the most common pattern on spirometry is airflow obstruction, although mixed obstructive/restrictive, restrictive, or normal values may also be seen. There may be reduced forced expiratory volume (FEV<sub>1</sub>) or a reduced FEV<sub>1</sub>/forced vital capacity (FVC) ratio of less than 70%, and the ratio of residual volume to total lung capacity (RV/TLC) may be increased (due to air trapping). It is usual for the FVC and TLC to be normal or low [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BMJ, 2020</a>].  </li><li>In children over 5 years of age with bronchiectasis the most frequent finding is airflow obstruction with reduced forced expiratory volume (FEV<sub>1</sub>), reduced forced expiratory flow (FEF)<sub>25–75</sub>, and increased RV and/or RV/TLC. FVC tends to be within normal limits or slightly reduced [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2010</a>].</li></ul><h5>Assessing for anxiety and depression</h5><ul><li>Anxiety and depression are more common in people with bronchiectasis, and they also have a lower quality of life. Depression is positively correlated with exercise limitation due to breathlessness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2019</a>].<ul><li>The recommendation to assess for anxiety and depression is pragmatic and what CKS considers good clinical practice.</li></ul></li></ul><h5>Documenting smoking history</h5><ul><li>The recommendation to document smoking history and to offer support to stop smoking is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Calculating the body mass index (BMI)</h5><ul><li>The BTS recommends recording the person's weight and calculating their BMI (this is a good practice recommendation) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2019</a>]. </li><li>A BMI of less than 18.5 in the Bronchiectasis Severity Index (BSI) clinical scoring system (which combines age, body mass index, FEV<sub>1</sub>, previous hospitalization, exacerbation frequency, colonization status, and radiological appearances) is a significant factor when assessing diseases severity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2019</a>]. <ul><li>If the person's BMI is less than 20 specialist nutritional advice should be sought [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Gruffydd-Jones, 2019</a>].</li></ul></li></ul><h5>Measuring specific antibody levels against capsular polysaccharides of <em>Streptococcus pneumoniae </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2019</a>]</h5><ul><li>BTS recommends that specific antibody levels against capsular polysaccharides of <em>S. pneumoniae</em> should be measured to investigate for specific antibody deficiency. People with low pneumococcal antibodies should be immunized with the 23 valent polysaccharide pneumococcal vaccine, followed by repeat measurement of specific antibody levels 4–8 weeks later (this is a grade D recommendation).</li></ul><h5>BTS grades of recommendations</h5><ul><li>Grade A: at least one meta-analysis, systematic review, or randomized controlled trial (RCT) rated as 1++ and directly applicable to the target population or a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results.</li><li>Grade B: a body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results or extrapolated evidence from studies rated as 1++ or 1+.</li><li>Grade C: a body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results or extrapolated evidence from studies rated as 2++.</li><li>Grade D: evidence of level 3 or 4 or extrapolated evidence from studies rated as 2+.</li><li>Good practice: important practical points for which there is no research evidence, nor is there likely to be any research evidence.</li></ul><!-- end field 685a0df4-db13-478b-9723-6965d6624136 --><!-- end item 1a8b5e3a-1459-4412-8468-7ff497b700aa -->","subChapters":[]}]},{"id":"38fe3441-facc-50ae-9366-6928aca6e388","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field c44668b4-88fa-4c76-8770-f084906b4c0e --><h3>How should I follow up a person who has been diagnosed with bronchiectasis?</h3><!-- end field c44668b4-88fa-4c76-8770-f084906b4c0e -->","summary":null,"htmlStringContent":"<!-- begin item 79aa14b1-4537-40a8-ab9c-77de1ff047c0 --><!-- begin field 07263a64-78ba-4a00-85f4-90bd5d545462 --><ul><li><strong>People at high risk of future exacerbations and all children should be reviewed in secondary care.</strong></li><li><strong>People at lower risk can be reviewed in primary care.</strong><br><ul><li>A baseline severity score may have been calculated in secondary care using a tool such as the <a href=\"http://www.bronchiectasisseverity.com/15-2/\" data-hyperlink-id=\"2e4dcff0-b09e-4e41-9dd8-a9ba00b87d2d\">Bronchiectasis Severity Index</a>. </li></ul></li><li><strong>Review people with bronchiectasis at least annually, including: </strong><ul style=\"font-weight: 400;\"><li style=\"font-weight: 400;\">An assessment of symptoms and how they affect their daily lives — offer pulmonary rehabilitation to people with breathlessness that affects their daily lives.</li><li style=\"font-weight: 400;\">Measurement of BMI — if the person's BMI is less than 20 seek specialist nutritional advice.</li><li style=\"font-weight: 400;\">The exacerbation frequency — refer people with three or more infective exacerbations a year, and people with fewer exacerbations that are causing significant morbidity to a respiratory specialist. These people might be considered for long-term prophylactic antibiotic treatment.</li><li style=\"font-weight: 400;\">Taking a sputum sample for bacterial culture — specialist follow up is required for people with chronic colonization with <em>Pseudomonas aeruginosa</em>, opportunist <em>Mycobacteria, </em>or methicillin-resistant <em>Staphylococcus aureus</em> (MRSA). </li><li style=\"font-weight: 400;\">The <a href=\"https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-scale-mrc-breathlessness-scale/\" data-hyperlink-id=\"27220dc5-d645-4bc8-a8c2-a9ba00b87e73\">Medical Research Council dyspnoea scale</a>. </li><li>Spirometry.</li><li style=\"font-weight: 400;\">Oxygen saturation levels.</li><li style=\"font-weight: 400;\">Compliance with sputum clearance exercises.</li></ul></li><li><strong>Do not repeat chest X-rays unless clinically indicated. </strong></li><li><strong>Offer people who smoke advice and support to help them stop</strong> — for further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>. </li><li><strong>Offer immunization</strong> against <em>Streptococcus pneumoniae</em> and seasonal influenza. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-pneumococcal/\">Immunizations - pneumococcal</a> and <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-seasonal-influenza/\">Immunizations - seasonal influenza</a>.</li><li><strong>Ensure all people with bronchiectasis:</strong><ul><li>Understand the condition, know how to recognize exacerbations and what to do if they experience them — a <a href=\"https://www.blf.org.uk/Page/Bronchiectasis\" data-hyperlink-id=\"0bfa306c-ec20-4e89-b73c-a98f00091be9\">patient information leaflet</a> on bronchiectasis is available from the British Lung Foundation.</li><li>Have been taught an airway clearance technique by a physiotherapist. <ul><li>Refer the person to a physiotherapist if they have not been taught an airway clearance technique.</li></ul></li></ul></li></ul><!-- end field 07263a64-78ba-4a00-85f4-90bd5d545462 --><!-- end item 79aa14b1-4537-40a8-ab9c-77de1ff047c0 -->","subChapters":[{"id":"4a72ca34-fcfd-53b8-af5e-780121a0c8d8","slug":"basis-for-recommendation-3c4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5872128f-344d-4b43-a936-0c6f0cfda668 --><h4>Basis for recommendation</h4><!-- end field 5872128f-344d-4b43-a936-0c6f0cfda668 -->","summary":null,"htmlStringContent":"<!-- begin item 3c49bb2c-480f-450c-a77f-ad64d641d4e7 --><!-- begin field 573c1b04-6a4d-42c6-a8c5-114606e05e92 --><p>These recommendations are based on the British Thoracic Society (BTS) <em>Guideline for non-CF bronchiectasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2010</a>], the <em>BTS Guideline for bronchiectasis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2019</a>], and expert opinion in a narrative review <em>Primary care implications of the British Thoracic Society Guidelines for bronchiectasis in adults 2019</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Gruffydd-Jones, 2019</a>].</p><h5>Smoking cessation</h5><ul><li>The recommendation to offer smoking cessation advice to people with bronchiectasis is pragmatic, based on what CKS considers to be good medical practice. </li></ul><h5>Frequency of monitoring [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">BTS, 2019</a>]</h5><ul><li>People with bronchiectasis should undergo routine monitoring to identify disease progression, pathogen emergence, and to modify treatment when necessary (this is a grade D recommendation).<ul><li>People should be assessed annually, however, the frequency should be tailored to the person's disease severity — people with more severe disease should be assessed more frequently (this is a good practice recommendation).</li></ul></li></ul><!-- end field 573c1b04-6a4d-42c6-a8c5-114606e05e92 --><!-- end item 3c49bb2c-480f-450c-a77f-ad64d641d4e7 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}